Biotech's Dumbest CEO Moves in 2016

Biotech's Dumbest CEO Moves in 2016


Investing in biotech companies isn't easy, but it seems likely that leading them is even harder. Ultimately the destiny of the company is mostly out of the CEO's hand once the clinical trial starts; either the drug candidate works or it doesn't.



from Biotech News